Organization · Venture Capital
LYFE Capital
LYFE Capital is a healthcare investment platform focused on critical healthcare supply chain assets and next-generation R&D services. With offices in Asia and the U.S., it aims to leverage cross-border opportunities in the healthcare sector.
Overview
What LYFE Capital does
What LYFE Capital is
LYFE Capital is a healthcare investment platform focused on critical healthcare supply chain assets and next-generation R&D services. With offices in Asia and the U.S., it aims to leverage cross-border opportunities in the healthcare sector.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2015
- Approximate age
- About 11 years
- Structured capabilities
- Funder
- Last reviewed
- March 18, 2026
Official channels
Find LYFE Capital elsewhere
Open the official website or a supported primary organization account.
Capability profile
LYFE Capital as a funder
Investment thesis
LYFE Capital focuses on investing in critical healthcare supply chain assets and next-generation R&D services, leveraging cross-border opportunities between Asia and the U.S. to drive growth in the healthcare sector.
Focus narrative
LYFE Capital invests in healthcare companies that are pivotal to the global healthcare ecosystem. The organization emphasizes building substantial positions in high-growth potential leaders, with a strategy that includes geographic revenue expansion and bolt-on acquisitions. This approach allows LYFE Capital to capitalize on the strengths of both Asian markets and U.S. innovation.
Value beyond capital
LYFE Capital adds value to its portfolio companies through strategic guidance in geographic expansion, operational efficiencies, and leveraging cross-border synergies between Asian and U.S. markets. The firm’s deep industry expertise and extensive network facilitate growth and innovation within its investments.
Focus and fit
- Stages
- Seed · Series A · Series B · Series C · Growth Equity
- Sectors
- Healthcare · Biotech · Pharma Tech · Health Data
- Regions
- Asia · Global · North America
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 108
- Recorded notable exits
- Cytek Biosciences, Burning Rock, Kyverna Therapeutics, and Pliant Therapeutics
Portfolio context
LYFE Capital manages a strategic portfolio of leading healthcare companies, including: Fong’s Engineering: A Singapore-based MedTech CDMO specializing in endoscopic solutions. Bora Pharmaceuticals: A global drug development and manufacturing company with strong M&A capabilities. ST Pharm: A South Korean leader in oligonucleotide synthesis, collaborating with major pharmaceutical firms. Jeisys Medical: A South Korean company focused on energy-based medical aesthetic devices. Noah Medical: A California-based surgical robotics firm specializing in endoluminal robotics. Profound Bio: A Seattle-headquartered ADC platform with ongoing clinical trials. Edge Medical: A China-based surgical robotics company with approved endoscopy systems.
Common questions
What to know about LYFE Capital
Upseed classifies LYFE Capital under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
March 18, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.